Anti-IL5R and other treatment approaches in the management of EGPA

BTS hosted the following webinar on 7 October 2025:

Anti-IL5R and other treatment approaches in the management of EGPA

Speakers: Prof David Jackson (London) & Dr Rona Smith (Cambridge)

Benralizumab has recently become the first NICE-approved biologic treatment for Eosinophilic granulomatosis with polyangiitis (EGPA). This rare heterogeneous condition is defined by the presence of eosinophilic inflammation leading to clinical remission rates of approximately 60% with benralizumab. However, other inflammatory pathways are frequently involved requiring a personalised multidisciplinary approach to management.

In this webinar the speakers reviewed clinical trial data, the new NICE guidance and discussed how to approach and manage patients with EGPA.